Keryx Biopharmaceuticals Inc. (KERX) Fundamentals

Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.
SHARE INFORMATION
Market Cap$ 404,463,111
Shares Outstanding120,375,926
Float112,754,495
Percent Float93.67%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 60,641,000
Latest Fiscal EPS$ -1.43
Latest Fiscal Date2017-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions263
Institutional Holdings Date2018-11-30
Institutional Bought Previous 3 Months3,885,182
Institutional Holdings Percent73.1%
Institutional Sold Previous 3 Months3,000,716
Insider Holdings Date2018-11-30
Insider Bought Previous 3 Months-
Insider Holdings Percent6.3
Insider Sold Previous 3 Months6,858
Insider Shares Owned7,621,431
TRADING INFO
52 Week High$ 5.98
52 Week Low$ 2.47
52 Week High Change$ -24.66
21 Day Moving Average$ 3.0833
21 Day Extended Moving Average$ 3.179
50 Day Moving Average$ 3.0562
50 Day Extended Moving Average$ 3.1378
200 Day Moving Average$ 3.9463
200 Day Extended Moving Average$ 3.8355
10 Day Average Volume819,930
20 Day Average Volume1,432,430
30 Day Average Volume1,380,312
50 Day Average Volume1,162,079
Alpha-0.016125
Beta1.7866
Standard Deviation0.173237
R20.105236
7 Day Price Change$ 0.00
7 Day Percent Change0.0%
21 Day Price Change$ 0.36
21 Day Percent Change12.0%
30 Day Price Change$ 0.66
30 Day Percent Change24.44%
Month to Date Price Change$ 0.35
Month to Date Percent Change11.63%
Quarter to Date Price Change$ -0.04
Quarter to Date Percent Change-1.18%
180 Day Price Change$ -1.83
180 Day Percent Change-35.26%
200 Day Price Change$ -1.92
200 Day Percent Change-36.36%
Year to Date Price Change$ -1.29
Year to Date Percent Change-27.74%

Keryx Biopharmaceuticals Inc. (KERX) Key Ratios

PROFITABILITY
EBIT Margin-30.4%
EBITDA Margin-29.4%
Pre-Tax Profit Margin-672.8%
Profit Margin Count-96.41%
Gross Margin62.5%
Profit Margin TOT-96.41%
INCOME STATEMENTS
Revenue$ 94,218,000
Revenue Per Share$ 0.7827
Revenue (3 Years)$ 90.54
Revenue (5 Years)$ 67.14
FINANCIAL STRENGTH
Price to Tangible Book-7.00
Total Debt To Equity0.00
Int Coverage-0.50
Current Ratio2.20
Leverage Ratio-4.20
Quick Ratio1.00
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio0.00
Enterprise Value$ 510,619,111
Price to Sales4.2928
Price to Free Cash-4.10
PE High Last 5 Years0.00
Price To Book61.60
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book-7.00
MANAGEMENT EFFECTIVENESS
Receivables Turnover4.30
Invoice Turnover0.80
Assets Turnover0.20
Return Assets-55.80
Return on Equity401.43
Return on Capital0.00

Keryx Biopharmaceuticals Inc. (KERX) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorUHY LLP
CEO-
Emplyoees189
Last AuditUQ
CIK0001114220
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
AddressOne Marina Park Drive, 12th Floor
Boston, MA 2210
Websitehttp://www.keryx.com
Facsimile+1 617 466-3501
Telephone+1 617 466-3500
EmailIR@keryx.com


Your Recent History
NASDAQ
KERX
Keryx Biop..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.